J.P. Morgan Recaps Amylin Pharmaceuticals Data

J.P. Morgan is recapping script data from Amylin Pharmaceuticals, Inc. AMLN. “In this note, we recap key script data in the diabetes drug landscape with a focus on the GLP-1 market,” J.P. Morgan writes. “Specifically for the week ended June 3, Byetta TRx was low and NRx was in line with the group while Victoza recorded the lowest NRx and TRx growth after a strong jump last week. Overall, total wk/wk GLP-1 script growth was weak.” Amylin Pharmaceuticals closed Monday at $12.05.